186 related articles for article (PubMed ID: 20104649)
21. Predictive and prognostic value of ER-α36 expression in breast cancer patients treated with chemotherapy.
Yu L; Ke W; Wang Y; Ding W; Wang B; Huang S; Chen J; Wang X; Wang Z; Shen P
Steroids; 2014 Jun; 84():11-6. PubMed ID: 24632025
[TBL] [Abstract][Full Text] [Related]
22. Lower expression of ER-α36 is associated with the development of endometrial hyperplasia in PCOS patients.
Lin SL; Tu BB; Du XG; Yan LY; Qiao J
Histol Histopathol; 2013 Nov; 28(11):1491-8. PubMed ID: 23690166
[TBL] [Abstract][Full Text] [Related]
23. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66.
Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
Biochem Biophys Res Commun; 2005 Nov; 336(4):1023-7. PubMed ID: 16165085
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
25. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
[TBL] [Abstract][Full Text] [Related]
26. A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis.
Deng H; Huang X; Fan J; Wang L; Xia Q; Yang X; Wang Z; Liu L
Oncol Rep; 2010 Jul; 24(1):171-6. PubMed ID: 20514458
[TBL] [Abstract][Full Text] [Related]
27. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
28. Expression of an estrogen receptor alpha variant protein in cell lines and tumors.
Fasco MJ; Keyomarsi K; Arcaro KF; Gierthy JF
Mol Cell Endocrinol; 2000 Aug; 166(2):156-69. PubMed ID: 11203301
[TBL] [Abstract][Full Text] [Related]
29. Biphasic ER-α36-mediated estrogen signaling regulates growth of gastric cancer cells.
Wang X; Huang X; Fu Z; Zou F; Li Y; Wang Z; Liu L
Int J Oncol; 2014 Dec; 45(6):2325-30. PubMed ID: 25231129
[TBL] [Abstract][Full Text] [Related]
30. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues.
Poola I; Speirs V
J Steroid Biochem Mol Biol; 2001 Nov; 78(5):459-69. PubMed ID: 11738556
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line.
Madsen MW; Reiter BE; Lykkesfeldt AE
Mol Cell Endocrinol; 1995 Apr; 109(2):197-207. PubMed ID: 7664983
[TBL] [Abstract][Full Text] [Related]
32. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
Adewumi AT; Mosebi S
Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
[TBL] [Abstract][Full Text] [Related]
33. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
[TBL] [Abstract][Full Text] [Related]
34. Progress in the Understanding of Estrogen Receptor Alpha Signaling in Triple-Negative Breast Cancer: Reactivation of Silenced ER-α and Signaling through ER-α36.
Al-Kabariti AY; Abbas MA
Mol Cancer Res; 2023 Nov; 21(11):1123-1138. PubMed ID: 37462782
[TBL] [Abstract][Full Text] [Related]
35. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors.
Gu Y; Chen T; López E; Wu W; Wang X; Cao J; Teng L
J Transl Med; 2014 Jan; 12():16. PubMed ID: 24447535
[TBL] [Abstract][Full Text] [Related]
36. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.
Pan X; Zhao B; Song Z; Han S; Wang M
J Pharmacol Sci; 2016 Feb; 130(2):85-93. PubMed ID: 26810571
[TBL] [Abstract][Full Text] [Related]
38. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
[TBL] [Abstract][Full Text] [Related]
39. ER-α36: a novel biomarker and potential therapeutic target in breast cancer.
Su X; Xu X; Li G; Lin B; Cao J; Teng L
Onco Targets Ther; 2014; 7():1525-33. PubMed ID: 25210466
[TBL] [Abstract][Full Text] [Related]
40. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
